When the new European In Vitro Diagnostic Regulation (IVDR) becomes applicable, the ability to utilize in-house or Laboratory Developed Tests (LDTs) will be much more restrictive in Europe. The testing landscape for companion diagnostics (CDx) will change, and pharma, molecular laboratories, and diagnostic providers need to ensure that patients have access to regulated tests. This webinar is specifically for those working in pharma business development, CDx alliance management and CDx commercialization management, project management and clinical trial management.

Join us to learn what clinical data need to be generated to meet IVDR requirements for CDx, how clinical trial programs may be impacted and how to make an IVDR-compliant CDx accessible to patients throughout Europe.